Trerief ' Analysis and Estimates from 2009 to 2020

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Trerief ' Analysis and Estimates from 2009 to 2020
Published on October 2011

Report Summary


Summary

GlobalData's pharmaceuticals report, 'Trerief ' Analysis and Estimates from 2009 to 2020' provides Trerief sales estimates for US and
EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis
of sales performance during the forecast period (2009-2020). The report also includes information on Parkinson's Disease market.
This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research
using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and
industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the Japan (seven major markets)
- Analysis and review of Trerief including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Trerief including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2011-2020 for Trerief in the Japan
-

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4
2.1 Parkinson's Disease 4

Trerief ' Analysis and Estimates from 2009 to 2020 (From Slideshare) Page 1/5


2.2 Symptoms of Parkinson's Disease 4
2.3 Diagnosis of Parkinson's Disease 5
2.4 Parkinson's Disease Treatment Strategies 5
2.5 Parkinson's Disease Market 6
2.6 Epidemiology 6
2.7 Parkinson's Disease by Age and Gender 6
2.8 Etiology 7
2.9 GlobalData Report Guidance 7
3 Parkinson's Disease: Market Characterization 8
3.1 Parkinson's Disease Market 8
3.2 Parkinson's Disease Market Forecasts and CAGR 8
3.3 Factors Affecting Parkinson's Disease Market 9
3.3.1 High Prevalence: Parkinson's Disease is the Second Most Frequent Neurodegenerative Disorder 9
3.3.2 Increase in Old Age Population 9
3.3.3 Patent Expiry of Prominent Drugs 9
4 Stages of Parkinson's Disease and Comparison of Treatments 10
4.1 The Hoehn and Yahr Scale 10
4.2 Modified Hoehn and Yahr Scale 10
4.3 The UPDRS 11
5 Staging of Parkinson's Disease 14
5.1 Distribution of Parkinson's Disease Patients by Age Groups 14
5.2 Distribution of Patients by Stages 14
6 Trerief 15
6.1 Introduction 15
6.2 Mechanism of Action 15
6.3 Clinical Studies 15
6.4 Approval History of Trerief 16
6.5 Factors Affecting Sales of Trerief 16
6.5.1 Absence of Trerief in the US and EU Market 16
6.5.2 Only Drug for Second Line Therapy of Parkinson's Disease 16
6.5.3 Unmet Medical Need 16
6.6 Drug Evaluation 16
6.6.1 Drug Risk Benefit Score 16
6.6.2 Intensity of Competition 17
6.7 Sales Estimates 18
6.7.1 Target Patient Pool for Parkinson's disease 18
6.7.2 Dosing 18
6.7.3 Market Penetration 19
6.7.4 Annual Cost of Therapy 19
6.7.5 Sales Estimates of Trerief in Japan 20
7 Parkinson Disease Market: Appendix 21
7.1 Market Definitions 21
7.2 List of Abberiviations 21
7.3 Research Methodology 21
7.3.1 Coverage 21
7.3.2 Secondary Research 21
7.3.3 Forecasting 22
7.3.4 Number of Patients Approved to take the Drug 22



7.3.5 Net Penetration of Drug 22
7.3.6 Net Annual Dosing 23
7.3.7 Annual Cost of Therapy 23
7.3.8 Primary Research 23
7.3.9 Expert Panels 24
7.4 Drug Sales Estimates Model 24
7.5 Contact Us 24
7.6 Disclaimer 25
7.7 Sources 25

1.1 List of Tables

Table 1: Clinical Motor and Nonmotor Features of Parkinson's Disease 4
Table 2: Hoehn and Yahr Stages of Parkinson's Disease 10
Table 3: Hoehn and Yahr Stages of Parkinson's Disease 10
Table 4: Four Items, Part 1 of UPDRS 11
Table 5: Thirteen Items, Part 2 of UPDRS 11
Table 6: Fourteen Items, Part 3 of UPDRS 12
Table 7: Fourteen Items, Part 3 of UPDRS 12
Table 8: Distribution of Parkinson's Patients According to Hoehn and Yahr Classification 14
Table 9: Change in UPDRS Part III from Baseline in Phase III Clinical Trials 15
Table 10: Approval History of Trerief 16
Table 11: Drug Risk Benefit Score of Trerief 17
Table 12: Summary of Adverse Events 17
Table 13: Annual Cost of Trerief for Parkinson's Disease, 2010 19
Table 14: Trerief, Parkinson's Disease, Japan, Sales Estimates ($m), 2009-2020 20

1.2 List of Figures

Figure 1: Current Pharmacologic Therapies for Parkinson's Disease and Their Potential Sites of Action in the CNS 5
Figure 2: The Age-Specific Prevalence Rates of Parkinson's Disease in the Elderly Among Five European Countries, 2003 6
Figure 3: Parkinson's Disease, Global, Market Size Estimates ($bn), 2010'2020 8
Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050 9
Figure 5: Points Distribution of UPDRS 13
Figure 6: Distribution of Parkinson's Disease Patients by Hoehn & Yahr Classification 14
Figure 7: Drug Model Diagram of Trerief 18
Figure 8: Trerief, Parkinson's Disease, Japan, Sales Estimates ($m), 2009-2020 20
Figure 9: Drug Model Diagram 23
Figure 10: Patients Approved for the Drug 23


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Trerief ' Analysis and Estimates from 2009 to 2020

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Trerief ' Analysis and Estimates from 2009 to 2020